Definitive Healthcare (DH) - 2025 Q2 - Quarterly Results

Financial Performance and Outlook This section details Definitive Healthcare's recent financial results and updated business outlook for 2025 Second Quarter 2025 Financial Highlights Q2 2025 revenue decreased 5% to $60.8M, net loss significantly improved, and full-year guidance was raised Q2 2025 Key Financial Metrics | Metric | Q2 2025 (M) | Q2 2024 (M) | Change | | :--- | :--- | :--- | :--- | | Revenue | $60.8M | $63.7M | -5% | | Net Loss | $(9.3)M | $(306.2)M | N/A | | Adjusted Net Income | $9.7M | $14.2M | -31.7% | | Adjusted EBITDA | $18.7M | $20.9M | -10.5% | | Adjusted EBITDA Margin | 31% | 33% | -200 bps | | Cash Flow from Operations | $9.3M | N/A | N/A | | Unlevered Free Cash Flow | $11.5M | N/A | N/A | - The significant reduction in Net Loss year-over-year is primarily due to the absence of the $363.6 million goodwill impairment charge that was recorded in Q2 2024[4] - Citing progress in the first half of the year, the company is increasing the midpoint of its revenue guidance and raising its adjusted EBITDA outlook for the full year 2025[4] Recent Business and Operating Highlights The company secured new and expanded customer contracts, highlighting superior data quality and custom reporting capabilities - Definitive Healthcare continues to win new logos and expand existing relationships across all its end-markets[5] - Key competitive advantages highlighted in recent wins include superior data quality, custom reporting capabilities (especially for claims analytics), and seamless integration with other platforms like HubSpot[5] Business Outlook The company issued Q3 2025 guidance and updated its full-year 2025 outlook, raising revenue and Adjusted EBITDA forecasts Third Quarter 2025 Guidance Specific financial guidance for Q3 2025, including revenue and profitability ranges, has been provided Q3 2025 Financial Guidance | Metric | Guidance Range (M) | | :--- | :--- | | Revenue | $59.0M – $60.0M | | Adjusted Operating Income | $12.5M – $13.5M | | Adjusted EBITDA | $15.5M – $16.5M | | Adjusted EBITDA Margin | 26% – 28% | | Adjusted Net Income | $7.5M – $8.5M | | Adjusted Net Income Per Diluted Share | $0.05 – $0.06 | Full Year 2025 Guidance Definitive Healthcare updated its full-year 2025 financial guidance, increasing revenue and Adjusted EBITDA projections Full Year 2025 Financial Guidance | Metric | Guidance Range (M) | | :--- | :--- | | Revenue | $237.0M – $240.0M | | Adjusted Operating Income | $52.0M – $55.0M | | Adjusted EBITDA | $64.0M – $67.0M | | Adjusted EBITDA Margin | 27% – 28% | | Adjusted Net Income | $32.5M – $34.5M | | Adjusted Net Income Per Diluted Share | $0.22 – $0.23 | - The company raised the bottom end of its prior full-year revenue range by $3.0 million[10] Financial Statements This section presents the company's condensed consolidated balance sheets, statements of operations, and cash flows Condensed Consolidated Balance Sheets Total assets decreased to $770.1M as of June 30, 2025, primarily due to reduced goodwill, while liabilities also declined Key Balance Sheet Items (in thousands) | Account | June 30, 2025 (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | Cash and cash equivalents | $80,984 | $105,378 | | Goodwill | $216,752 | $393,283 | | Total assets | $770,145 | $1,089,389 | | Term loan (Current + Long term) | $169,035 | $243,118 | | Total liabilities | $358,912 | $482,195 | | Total equity | $411,233 | $607,194 | Condensed Consolidated Statements of Operations Q2 2025 revenue was $60.8M, with net loss significantly improving to $(9.3)M due to the absence of goodwill impairment Statement of Operations Highlights (in thousands) | Metric | Three Months Ended June 30, 2025 (in thousands) | Three Months Ended June 30, 2024 (in thousands) | | :--- | :--- | :--- | | Revenue | $60,750 | $63,737 | | Gross Profit | $46,613 | $50,454 | | Loss from Operations | $(4,170) | $(369,641) | | Goodwill Impairment | $0 | $363,641 | | Net Loss | $(9,265) | $(306,187) | | Net Loss per Share | $(0.07) | $(1.81) | - For the six months ended June 30, 2025, the company recorded a goodwill impairment charge of $176.5 million[31] Condensed Consolidated Statements of Cash Flows Net cash from operations was $9.3M in Q2 2025, with significant cash used in financing activities, leading to a net decrease Cash Flow Summary (in thousands) | Cash Flow Activity | Three Months Ended June 30, 2025 (in thousands) | Six Months Ended June 30, 2025 (in thousands) | | :--- | :--- | :--- | | Net cash provided by operating activities | $9,304 | $35,370 | | Net cash (used in) provided by investing activities | $(10,162) | $73,383 | | Net cash used in financing activities | $(24,700) | $(134,406) | | Net (decrease) in cash | $(25,558) | $(25,653) | | Cash and cash equivalents, end of period | $80,984 | $80,984 | - Significant cash outflows in financing activities for the six-month period included repayments of the term loan ($248.4M), repurchases of Class A Common Stock ($40.2M), and payments under the tax receivable agreement ($13.8M), partially offset by proceeds from a new term loan ($175.0M)[33] Non-GAAP Financial Measures and Reconciliations This section defines and reconciles the company's non-GAAP financial measures to their most directly comparable GAAP equivalents Explanation of Non-GAAP Financial Measures The company uses non-GAAP measures like Adjusted EBITDA to assess core operational performance by excluding non-recurring items - The company presents non-GAAP financial measures to help investors evaluate its core operations by excluding certain significant or unusual items[19] - Key non-GAAP measures include Unlevered Free Cash Flow, Adjusted EBITDA, Adjusted Gross Profit, Adjusted Operating Income, and Adjusted Net Income[20] - Adjusted EBITDA is a key metric used by management and the board to assess profitability, excluding items like interest, taxes, depreciation, amortization, equity-based compensation, and goodwill impairments[22] Reconciliation of GAAP to Non-GAAP Measures Detailed tables reconcile GAAP results to non-GAAP metrics, including Unlevered Free Cash Flow, Adjusted Net Income, and EBITDA Reconciliation of GAAP Operating Cash Flow to Unlevered Free Cash Flow This table reconciles GAAP net cash provided by operating activities to Unlevered Free Cash Flow (Non-GAAP) Unlevered Free Cash Flow Reconciliation (in thousands) | Metric | Three Months Ended June 30, 2025 (in thousands) | Three Months Ended June 30, 2024 (in thousands) | | :--- | :--- | :--- | | Net cash provided by operating activities (GAAP) | $9,304 | $14,040 | | Less: Purchases of property, equipment, etc. | $(2,293) | $(410) | | Add: Interest paid in cash | $2,959 | $3,590 | | Add: Transaction, integration, and restructuring expenses | $672 | $1,804 | | Add: Other non-core items | $836 | $2,438 | | Unlevered Free Cash Flow (Non-GAAP) | $11,478 | $21,462 | Reconciliation of GAAP Net Loss to Adjusted Net Income This table reconciles the GAAP net loss to the Adjusted Net Income (Non-GAAP) by detailing various adjustments Adjusted Net Income Reconciliation (in thousands) | Metric | Three Months Ended June 30, 2025 (in thousands) | Three Months Ended June 30, 2024 (in thousands) | | :--- | :--- | :--- | | Net loss (GAAP) | $(9,265) | $(306,187) | | Adjustments (Amortization, Equity Comp, Goodwill, etc.) | $18,809 | $377,802 | | Adjusted Operating Income | $15,639 | $19,304 | | Less: Other adjustments (Interest, Taxes, etc.) | $(5,963) | $(5,149) | | Adjusted Net Income (Non-GAAP) | $9,676 | $14,155 | | Adjusted Net Income Per Diluted Share | $0.07 | $0.09 | Reconciliation of GAAP Net Loss to Adjusted EBITDA This table reconciles GAAP net loss to Adjusted EBITDA (Non-GAAP) by adding back interest, taxes, D&A, and other adjustments Adjusted EBITDA Reconciliation (in thousands) | Metric | Three Months Ended June 30, 2025 (in thousands) | Three Months Ended June 30, 2024 (in thousands) | | :--- | :--- | :--- | | Net loss (GAAP) | $(9,265) | $(306,187) | | Add: Interest, Taxes, D&A | $16,035 | $(8,937) | | EBITDA | $6,770 | $(315,253) | | Add: Other adjustments (Equity Comp, Goodwill, etc.) | $11,886 | $336,172 | | Adjusted EBITDA (Non-GAAP) | $18,656 | $20,919 | | Adjusted EBITDA Margin | 31% | 33% | Other Information This section provides details on the upcoming conference call and important forward-looking statements Conference Call Information Definitive Healthcare will host a conference call on August 7, 2025, to discuss Q2 2025 financial results - A conference call to discuss Q2 2025 results is scheduled for August 7, 2025, at 5:00 p.m. EDT[11] Forward-Looking Statements The report contains forward-looking statements regarding future performance, subject to risks that could cause actual results to differ - The report includes forward-looking statements concerning financial guidance, future prospects, and market conditions, which are not guarantees of future performance[13] - Key risks that could cause actual results to differ include geopolitical tension, macroeconomic conditions, inability to acquire new customers, market competition, and potential security breaches[14]